In this podcast, experts will discuss the latest pharmacologic recommendations and their evolution in the treatment of cardiac amyloidosis. They will delineate the different potential therapeutic targets for the pharmacotherapy of cardiac amyloidosis including TTR silencing, stabilization, and disruption. Claim CE and MOC at https://bit.ly/ATTR-CM_series

In this podcast, experts will discuss the latest pharmacologic recommendations and their evolution in the treatment of cardiac amyloidosis. They will delineate the different potential therapeutic targets for the pharmacotherapy of cardiac amyloidosis including TTR silencing, stabilization, and disruption. Claim CE and MOC at https://bit.ly/ATTR-CM_series

In this podcast, experts will discuss the latest pharmacologic recommendations and their evolution in the treatment of cardiac amyloidosis. They will delineate the different potential therapeutic targets for the pharmacotherapy of cardiac amyloidosis including TTR silencing, stabilization, and disruption. Claim CE and MOC at https://bit.ly/ATTR-CM_series

Pharmacotherapy for Cardiac Amyloidosis

This series will discuss how further close the knowledge gaps in ATTR-CM that exist among healthcare professionals (HCPs) and improving care of patients with Transthyretin Cardiomyopathy.

Share Pharmacotherapy for Cardiac Amyloidosis

Sign up to save your podcasts

Pharmacotherapy for Cardiac Amyloidosis

Pharmacotherapy for Cardiac Amyloidosis

More shows like Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)

The NACE Clinical Highlights Show